Clinical Trial Update: Combination Therapy With NC-6004 and Pembrolizumab in Head and Neck Cancer Subjects Who Have Failed Platinum Regimen [Phase 2]

View source ↗

Summary

Phase 2 trial investigating NC-6004 plus pembrolizumab in head and neck cancer after platinum failure is underway but with unknown current status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• NC-6004 (cisplatin nanoparticle formulation)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: NanoCarrier Co., Ltd. | Conditions: SCCHN | Phase 2 | Status: UNKNOWN